MediLexicon News - ImmunoCellular Therapeutics To Present Today Data From Phase I Clinical Trial Of ICT-107 At Annual Meeting Of Congress Of Neurological Surgeons

news headlines

email to a friend

printer friendly

ImmunoCellular Therapeutics To Present Today Data From Phase I Clinical Trial Of ICT-107 At Annual Meeting Of Congress Of Neurological Surgeons

Main Category: Neurology / Neuroscience
Also Included In: Cancer / Oncology | Clinical Trials / Drug Trials
Article Date: 28 Oct 2009

ImmunoCellular Therapeutics, Ltd. (OTCBB: IMUC), a clinical-stage biotechnology company that is developing immune-based therapies for the treatment of brain and other cancers, today announced that it will be presenting today, at the Annual Meeting of the Congress of Neurological Surgeons in New Orleans, Louisiana at 3:15pm central time, data from its Phase I clinical trial investigating the role that its ICT-107 vaccine may play in increasing patient survival and inhibiting tumor progression in patients with glioblastoma, the most common and most aggressive type of primary brain tumor.

The company will hold a conference call on Tuesday, October 27th at 11 a.m. eastern time to discuss the data presented at the conference. Interested parties may access the call by dialing (877) 407-0778 domestically, or (201) 689-8565 internationally. A replay of the call will be available until November 10, 2009, and can be accessed by dialing (877) 660-6853 domestically, or (201)-612-7415 for international audiences, and using account # 286 and Conference ID #: 336119.

The call will also be available via a simultaneous live webcast, and can be accessed by visiting http://iq-vcall.incommsolutions.com and using InComm IQueue Conference Number: 00336119. Please note that webcast audiences must use Internet Explorer to access the broadcast.

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The company's "off the shelf" therapeutic vaccine product candidate targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the first quarter of 2010. IMUC also recently completed a Phase I trial of its dendritic cell-based clinical product candidate for glioblastoma. IMUC has entered into a research and license option deal with the Roche Group for one of its monoclonal antibodies for the diagnosis and treatment of ovarian cancer and multiple myeloma, that provides for potential licensing and milestone payments of $32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery using differential immunization for diagnosing and treating multiple types of cancer. To learn more about IMUC, please visit http://www.imuc.com.

Source
The Congress of Neurological Surgeons

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.

< back to medical news

For any corrections of factual information, or to contact the editors please use our feedback form.

Send your press releases to

ImmunoCellular Therapeutics To Present Today Data From Phase I Clinical Trial Of ICT-107 At Annual Meeting Of Congress Of Neurological Surgeons

PDA Medical Dictionary